Sakar Healthcare Limited Share Price

Equities

SAKAR

INE732S01012

Pharmaceuticals

Market Closed - NSE India S.E. 12:50:06 22/07/2024 BST 5-day change 1st Jan Change
327.7 INR -1.44% Intraday chart for Sakar Healthcare Limited -1.86% -18.09%

Financials

Sales 2022 1.29B 15.44M 1.19B Sales 2023 1.34B 16.04M 1.24B Capitalization 3.82B 45.67M 3.53B
Net income 2022 152M 1.82M 141M Net income 2023 128M 1.53M 118M EV / Sales 2022 2.46 x
Net Debt 2022 857M 10.25M 793M Net Debt 2023 1.16B 13.83M 1.07B EV / Sales 2023 3.71 x
P/E ratio 2022
15.2 x
P/E ratio 2023
29.2 x
Employees 297
Yield 2022 *
-
Yield 2023
-
Free-Float 99%
More Fundamentals * Estimated data
Dynamic Chart
Sakar Healthcare Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
Sakar Healthcare Ltd Receives EU GMP Approval Dated 5th March 2024With A Validity of Three Years from Audited Date CI
Sakar Healthcare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Sakar Healthcare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Sakar Healthcare Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Sakar Healthcare Limited announced that it expects to receive INR 599.999123 million in funding from Tata Investment Corporation Limited CI
Sakar Healthcare Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Sakar Healthcare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Sakar Healthcare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Indian shares seen opening lower; U.S. jobs data in focus RE
Sakar Healthcare Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Sakar Healthcare Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022 CI
Sakar Healthcare Limited Reports Earnings Results for the Full Year Ended March 31, 2022 CI
Sakar Healthcare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021 CI
Sakar Healthcare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021 CI
More news
1 day-1.44%
1 week-1.86%
Current month+4.25%
1 month+4.60%
3 months-8.55%
6 months-24.71%
Current year-18.09%
More quotes
1 week
326.10
Extreme 326.1
374.50
1 month
310.00
Extreme 310
374.50
Current year
295.15
Extreme 295.15
479.00
1 year
249.10
Extreme 249.1
479.00
3 years
103.35
Extreme 103.35
479.00
5 years
44.00
Extreme 44
479.00
10 years
44.00
Extreme 44
479.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 33 31/05/12
Chief Executive Officer 64 25/03/04
Director of Finance/CFO 58 30/10/21
Members of the board TitleAgeSince
Director/Board Member 72 27/09/20
Director/Board Member 63 31/03/15
Founder 59 25/03/04
More insiders
Date Price Change Volume
22/07/24 327.7 -1.44% 23 790
19/07/24 332.5 -6.63% 57,293
18/07/24 356.1 +6.73% 76,726
16/07/24 333.6 0.00% 10,330
15/07/24 333.6 -0.07% 19,102

Delayed Quote NSE India S.E., July 22, 2024 at 12:50 pm

More quotes
Sakar Healthcare Limited is an India-based pharmaceutical formulations company. The Company is engaged in manufacturing of pharmaceutical products providing liquid orals, cephalosporin tablet, capsule, dry powder syrup, dry powder injections, liquid injectable (SVP) in ampoules, vials & lyophilized injections, oral solid dosages and research & development of above products. The Company's oncology products include oral solid dosage (tablet & capsule), liquid injection, lyophilized injection, active pharmaceutical ingredient (API), CDMO products and CRAMs. The Company's product portfolio includes approximately 175 formulations for the international markets, 292 registered brands under its own name in more than 24 therapeutic areas. It has a presence across the regions of Africa (Anglo & Francophone), SEASIA, CIS, Latin & Central America and in Europe. The Company has set up a research-driven vertically integrated with API for oncology formulation manufacturing unit.
More about the company